Translating AMCP Nexus Data Into Care Strategy for Neurology and Mental Health

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion (DM-BUP) was associated with lower total health care costs compared with other therapies, outlining strategies managed care organizations can use to promote cost-effective treatment adoption.

Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to prevent high-cost care episodes, emphasizing the need for predictive analytics, streamlined access, and real-world comparative data to guide treatment sequencing decisions.

Zachary Contreras of Sharp Health Plan discusses how dextromethorphan-bupropion may improve agitation management in Alzheimer disease while reducing healthcare costs and supporting patient-centered care.

Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling timely intervention with dextromethorphan-bupropion and reducing clinical and economic burden.

Zachary Contreras highlighted strategies discussed at AMCP Nexus for improving timely access to monoclonal migraine receptor (MMR) therapy through updated coverage pathways, specialist input, and real-time benefit checks.

Zachary Contreras of Sharp Health Plan highlighted strategies discussed at AMCP Nexus for improving timely access to Monoclonal Migraine Receptor (MMR) therapy through updated coverage pathways, specialist input, and real-time benefit checks.

New data suggests dextromethorphan plus bupropion may offer managed care cost containment by increasing remission rates in depression.

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, and long-term safety data to reduce costly treatment-resistant depression.

Managed care organizations should evolve cost models to capture savings from dextromethorphan-bupropion’s safety profile, which avoids costly complications associated with traditional Alzheimer disease agitation therapies.

Managed care organization and providers should conduct early formulary reviews and education to ensure rapid access to dextromethorphan-bupropion upon approval, potentially delaying facility placement for patients with Alzheimer disease.